Diabetes, Vol 49, Issue 9 1399-1408, Copyright © 2000 by American Diabetes Association

ARTICLES

The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?

ML Caramori, P Fioretto and M Mauer
Department of Pediatrics, University of Minnesota, Minneapolis, USA.

Initial studies showing an approximately 80% rate of progression from microalbuminuria (MA) to proteinuria in type 1 diabetic patients led to the broad acceptance of MA as a useful clinical predictor of increased diabetic nephropathy (DN) risk. Some MA patients, however, have quite advanced renal structural changes, and MA may, in these cases, be a marker rather than a predictor of DN. More recent studies have observed only about a 30-45% risk of progression of MA to proteinuria over 10 years, while about 30% of type 1 diabetic patients with MA became normoalbuminuric and the rest remained microalbuminuric. The finding that some MA patients have only mild diabetic renal lesions is consistent with the lower than originally estimated risk of progression from MA to proteinuria and with the notion that some MA patients revert to normoalbuminuria. To increase the complexity of the scenario, some normoalbuminuric long-standing type 1 diabetic patients have well-established DN lesions and approximately 40% of all patients destined to progress to proteinuria are normoalbuminuric at initial screening, despite many years of diabetes. A similar picture is emerging in type 2 diabetic patients, although fewer studies have been conducted. Thus, the predictive precision for MA to progress to overt nephropathy over the subsequent decade or so is considerably less than originally described. It is unclear whether this is due to changes in the natural history of DN resulting from improved glycemia and blood pressure control, or whether there were overestimates of risk in the original studies due to the small sample sizes, post hoc analyses, and variable MA definitions. Albumin excretion rate (AER) remains the best available noninvasive predictor of DN risk and should be regularly measured according to established guidelines. However, AER may be unable to define patients who are safe from or at risk of DN with an accuracy that is adequate for optimal clinical decision making or for the design of certain clinical trials. Investigations into new risk markers or into the combined use of several currently available predictive parameters are needed.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				V.-P. Makinen, C. Forsblom, L. M. Thorn, J. Waden, D. Gordin, O. Heikkila, K. Hietala, L. Kyllonen, J. Kyto, M. Rosengard-Barlund, et al. Metabolic Phenotypes, Vascular Complications, and Premature Deaths in a Population of 4,197 Patients With Type 1 Diabetes Diabetes, September 1, 2008; 57(9): 2480 - 2487. [Abstract] [Full Text] [PDF]

				L. H. Ficociello, B. A. Perkins, K. H. Silva, D. M. Finkelstein, H. Ignatowska-Switalska, Z. Gaciong, L. A. Cupples, A. Aschengrau, J. H. Warram, and A. S. Krolewski Determinants of Progression from Microalbuminuria to Proteinuria in Patients Who Have Type 1 Diabetes and Are Treated with Angiotensin-Converting Enzyme Inhibitors Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 461 - 469. [Abstract] [Full Text] [PDF]

				L. M. Thorn, C. Forsblom, J. Fagerudd, K. Pettersson-Fernholm, R. Kilpikari, P.-H. Groop, and on behalf of the FinnDiane Study Group Clustering of Risk Factors in Parents of Patients With Type 1 Diabetes and Nephropathy Diabetes Care, May 1, 2007; 30(5): 1162 - 1167. [Abstract] [Full Text] [PDF]

				I. H. de Boer and M. W. Steffes Glomerular Filtration Rate and Albuminuria: Twin Manifestations of Nephropathy in Diabetes J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1036 - 1037. [Full Text] [PDF]

				P. Aaltonen, J. Rinta-Valkama, A. Patari, P. Tossavainen, T. Palmen, P. Kulmala, M. Knip, and H. Holthofer Circulating antibodies to nephrin in patients with type 1 diabetes Nephrol. Dial. Transplant., January 1, 2007; 22(1): 146 - 153. [Abstract] [Full Text] [PDF]

				E. E. Tchekneva, E. M. Rinchik, D. Polosukhina, L. S. Davis, V. Kadkina, Y. Mohamed, S. R. Dunn, K. Sharma, Z. Qi, A. B. Fogo, et al. A Sensitized Screen of N-ethyl-N-nitrosourea-Mutagenized Mice Identifies Dominant Mutants Predisposed to Diabetic Nephropathy J. Am. Soc. Nephrol., January 1, 2007; 18(1): 103 - 112. [Abstract] [Full Text] [PDF]

				N. Babic, T.S. Larson, S.K. Grebe, S.T. Turner, R. Kumar, and R.J. Singh Application of liquid chromatography-mass spectrometry technology for early detection of microalbuminuria in patients with kidney disease. Clin. Chem., November 1, 2006; 52(11): 2155 - 2157. [Full Text] [PDF]

				A. Fornoni, S. A. Rosenzweig, O. Lenz, A. Rivera, G. E. Striker, and S. J. Elliot Low Insulin-Like Growth Factor Binding Protein-2 Expression Is Responsible for Increased Insulin Receptor Substrate-1 Phosphorylation in Mesangial Cells from Mice Susceptible to Glomerulosclerosis Endocrinology, July 1, 2006; 147(7): 3547 - 3554. [Abstract] [Full Text] [PDF]

				R. Retnakaran, C. A. Cull, K. I. Thorne, A. I. Adler, R. R. Holman, and for the UKPDS Study Group Risk Factors for Renal Dysfunction in Type 2 Diabetes: U.K. Prospective Diabetes Study 74 Diabetes, June 1, 2006; 55(6): 1832 - 1839. [Abstract] [Full Text] [PDF]

				M. L. Caramori, P. Fioretto, and M. Mauer Enhancing the Predictive Value of Urinary Albumin for Diabetic Nephropathy J. Am. Soc. Nephrol., February 1, 2006; 17(2): 339 - 352. [Abstract] [Full Text] [PDF]

				M. E. Molitch, D. Rupp, and M. Carnethon Higher Levels of HDL Cholesterol Are Associated With a Decreased Likelihood of Albuminuria in Patients With Long-Standing Type 1 Diabetes Diabetes Care, January 1, 2006; 29(1): 78 - 82. [Abstract] [Full Text] [PDF]

				H. Kramer and M. E. Molitch Screening for Kidney Disease in Adults With Diabetes Diabetes Care, July 1, 2005; 28(7): 1813 - 1816. [Full Text] [PDF]

				J. M. Steinke, A. R. Sinaiko, M. S. Kramer, S. Suissa, B. M. Chavers, M. Mauer, and for the International Diabetic Nephropathy Study G The Early Natural History of Nephropathy in Type 1 Diabetes: III. Predictors of 5-Year Urinary Albumin Excretion Rate Patterns in Initially Normoalbuminuric Patients Diabetes, July 1, 2005; 54(7): 2164 - 2171. [Abstract] [Full Text] [PDF]

				V. Baskar, D. Kamalakannan, B. Kiberd, M.R. Holland, and B.M. Singh Hypertension-based clinical risk strategies for detecting microalbuminuria in diabetes QJM, June 1, 2005; 98(6): 427 - 433. [Abstract] [Full Text] [PDF]

				C. Yagil, A. Barak, D. Ben-Dor, E. Rosenmann, J. Bernheim, M. Rosner, Y. Segev, S. Weksler-Zangen, I. Raz, and Y. Yagil Nonproteinuric Diabetes-Associated Nephropathy in the Cohen Rat Model of Type 2 Diabetes Diabetes, May 1, 2005; 54(5): 1487 - 1496. [Abstract] [Full Text] [PDF]

				M. J. Krimholtz, J. Karalliedde, S. Thomas, R. Bilous, and G. Viberti Targeting Albumin Excretion Rate in the Treatment of the Hypertensive Diabetic Patient with Renal Disease J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S42 - S47. [Abstract] [Full Text] [PDF]

				F. A. van Nieuwenhoven, L. J. N. Jensen, A. Flyvbjerg, and R. Goldschmeding Imbalance of growth factor signalling in diabetic kidney disease: is connective tissue growth factor (CTGF, CCN2) the perfect intervention point? Nephrol. Dial. Transplant., January 1, 2005; 20(1): 6 - 10. [Full Text] [PDF]

				J. L. Gross, M. J. de Azevedo, S. P. Silveiro, L. H. Canani, M. L. Caramori, and T. Zelmanovitz Diabetic Nephropathy: Diagnosis, Prevention, and Treatment Diabetes Care, January 1, 2005; 28(1): 164 - 176. [Abstract] [Full Text] [PDF]

				M. D. Breyer, E. Bottinger, F. C. Brosius III, T. M. Coffman, R. C. Harris, C. W. Heilig, K. Sharma, and for the AMDCC Mouse Models of Diabetic Nephropathy J. Am. Soc. Nephrol., January 1, 2005; 16(1): 27 - 45. [Abstract] [Full Text] [PDF]

				P. Roestenberg, F. A. van Nieuwenhoven, L. Wieten, P. Boer, T. Diekman, A. M. Tiller, W. M. Wiersinga, N. Oliver, W. Usinger, S. Weitz, et al. Connective Tissue Growth Factor Is Increased in Plasma of Type 1 Diabetic Patients With Nephropathy Diabetes Care, May 1, 2004; 27(5): 1164 - 1170. [Abstract] [Full Text] [PDF]

				K. Susztak, E. Bottinger, A. Novetsky, D. Liang, Y. Zhu, E. Ciccone, D. Wu, S. Dunn, P. McCue, and K. Sharma Molecular Profiling of Diabetic Mouse Kidney Reveals Novel Genes Linked to Glomerular Disease Diabetes, March 1, 2004; 53(3): 784 - 794. [Abstract] [Full Text] [PDF]

				J. T. Lane Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective Am J Physiol Renal Physiol, March 1, 2004; 286(3): F442 - F450. [Abstract] [Full Text] [PDF]

				M. L. Caramori, L. H. Canani, L. A. Costa, and J. L. Gross The Human Peroxisome Proliferator-Activated Receptor {gamma}2 (PPAR{gamma}2) Pro12Ala Polymorphism Is Associated With Decreased Risk of Diabetic Nephropathy in Patients With Type 2 Diabetes Diabetes, December 1, 2003; 52(12): 3010 - 3013. [Abstract] [Full Text] [PDF]

				G. Bruno, F. Merletti, A. Biggeri, G. Bargero, S. Ferrero, G. Pagano, and P. C. Perin Progression to Overt Nephropathy in Type 2 Diabetes: The Casale Monferrato Study Diabetes Care, July 1, 2003; 26(7): 2150 - 2155. [Abstract] [Full Text] [PDF]

				B. A. Perkins, L. H. Ficociello, K. H. Silva, D. M. Finkelstein, J. H. Warram, and A. S. Krolewski Regression of Microalbuminuria in Type 1 Diabetes N. Engl. J. Med., June 5, 2003; 348(23): 2285 - 2293. [Abstract] [Full Text] [PDF]

				B. Najafian, Y. Kim, J. T. Crosson, and M. Mauer Atubular Glomeruli and Glomerulotubular Junction Abnormalities in Diabetic Nephropathy J. Am. Soc. Nephrol., April 1, 2003; 14(4): 908 - 917. [Abstract] [Full Text] [PDF]

				M. L. Caramori, P. Fioretto, and M. Mauer Low Glomerular Filtration Rate in Normoalbuminuric Type 1 Diabetic Patients: An Indicator of More Advanced Glomerular Lesions Diabetes, April 1, 2003; 52(4): 1036 - 1040. [Abstract] [Full Text] [PDF]

				D. J. Brotman, J. P. Girod, S. Thomas, P. L. Poulsen, K. W. Hansen, C. E. Mogensen, M. L. Caramori, M. Pecis, M. J. Azevedo, R. Marfella, et al. Increase in Nocturnal Blood Pressure and Progression to Microalbuminuria in Diabetes N. Engl. J. Med., January 16, 2003; 348(3): 260 - 264. [Full Text] [PDF]

				E. Lurbe, J. Redon, A. Kesani, J. M. Pascual, J. Tacons, V. Alvarez, and D. Batlle Increase in Nocturnal Blood Pressure and Progression to Microalbuminuria in Type 1 Diabetes N. Engl. J. Med., September 12, 2002; 347(11): 797 - 805. [Abstract] [Full Text] [PDF]

				G. Gambaro, I. Kinalska, A. Oksa, P. Pont'uch, M. Hertlova, J. Olsovsky, J. Manitius, D. Fedele, S. Czekalski, J. Perusicova, et al. Oral Sulodexide Reduces Albuminuria in Microalbuminuric and Macroalbuminuric Type 1 and Type 2 Diabetic Patients: The Di.N.A.S. Randomized Trial J. Am. Soc. Nephrol., June 1, 2002; 13(6): 1615 - 1625. [Abstract] [Full Text] [PDF]

				H.-H. Parving, N. Chaturvedi, G. Viberti, and C. E. Mogensen Does Microalbuminuria Predict Diabetic Nephropathy? Diabetes Care, February 1, 2002; 25(2): 406 - 407. [Full Text]

				M. L. Caramori, Y. Kim, C. Huang, A. J. Fish, S. S. Rich, M. E. Miller, G. Russell, and M. Mauer Cellular Basis of Diabetic Nephropathy: 1. Study Design and Renal Structural-Functional Relationships in Patients With Long-Standing Type 1 Diabetes Diabetes, February 1, 2002; 51(2): 506 - 513. [Abstract] [Full Text] [PDF]

				A. M.E. Spoelstra-de Man, C. B. Brouwer, C. D.A. Stehouwer, and Y. M. Smulders Rapid Progression of Albumin Excretion Is an Independent Predictor of Cardiovascular Mortality in Patients With Type 2 Diabetes and Microalbuminuria Diabetes Care, December 1, 2001; 24(12): 2097 - 2101. [Abstract] [Full Text] [PDF]

				B. P. Tabaei, A. S. Al-Kassab, L. L. Ilag, C. M. Zawacki, and W. H. Herman Does Microalbuminuria Predict Diabetic Nephropathy? Diabetes Care, September 1, 2001; 24(9): 1560 - 1566. [Abstract] [Full Text] [PDF]

				M. A. Crook, J. C. Pickup, P. J. Lumb, F. Georgino, D. J. Webb, and J. H. Fuller Relationship Between Plasma Sialic Acid Concentration and Microvascular and Macrovascular Complications in Type 1 Diabetes: The EURODIAB Complications Study Diabetes Care, February 1, 2001; 24(2): 316 - 322. [Abstract] [Full Text]